A PET tracer for renal organic cation transporters, 11C-metformin: Radiosynthesis and preclinical proof-of-concept studies

Journal of Nuclear Medicine

Volumn 57, Issue 4, 2016, Pages 615-621

  Jakobsen, Steen ^a   Busk, Morten ^a   Jensen, Jonas Brorson ^a,b   Munk, Ole Lajord ^a   Zois, Nora Elisabeth ^a   Alstrup, Aage K O ^a   Jessen, Niels ^b   Frøkiær, Jørgen ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

Glomerular filtration rate; Metformin; Organic cation transporter; Positron emission tomography; Renal function

Indexed keywords

CARBON(N METHYL)METFORMIN C 11; CHROMIUM ETHYLENEDIAMINETETRAACETIC ACID C 51; CIMETIDINE; CISPLATIN; METFORMIN; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; QUININE; RADIOPHARMACEUTICAL AGENT; TETRABUTYLAMMONIUM; TRACER; UNCLASSIFIED DRUG; BIGUANIDE DERIVATIVE; EDETIC ACID; ORGANIC CATION TRANSPORTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG KIDNEY LEVEL; DRUG LIVER LEVEL; DRUG MECHANISM; DRUG POTENTIATION; DRUG PURITY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG UPTAKE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY FUNCTION; NONHUMAN; PIG; PRIORITY JOURNAL; RADIOACTIVITY; RADIOCHEMISTRY; RADIOSYNTHESIS; RAT; URINALYSIS; ANIMAL; AUTORADIOGRAPHY; CHEMISTRY; DOSE RESPONSE; KIDNEY; LIVER; LLC PK1 CELL LINE; METABOLISM; METHYLATION; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; SPRAGUE DAWLEY RAT; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; AUTORADIOGRAPHY; BIGUANIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; EDETIC ACID; ISOTOPE LABELING; KIDNEY; LIVER; LLC-PK1 CELLS; METFORMIN; METHYLATION; ORGANIC CATION TRANSPORT PROTEINS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; SWINE; TISSUE DISTRIBUTION;

EID: 84963956559     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.169292     Document Type: Article

References (36)

1. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007;24:1227-1251.
2. Urakami Y, Okuda M, Masuda S, Saito H, Inui KI. Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther. 1998;287:800-805.
3. Reznichenko A, Sinkeler SJ, Snieder H, et al. SLC22A2 is associated with tubular creatinine secretion and bias of estimated GFR in renal transplantation. Physiol Genomics. 2013;45:201-209.
4. Shim WS, Park JH, Ahn SJ, et al. Testosteroneindependent down-regulation of Oct2 in the kidney medulla from a uranyl nitrate-induced rat model of acute renal failure: effects on distribution of a model organic cation, tetraethylammonium. J Pharm Sci. 2009;98:739-747.
5. Matsuzaki T, Morisaki T, Sugimoto W, et al. Altered pharmacokinetics of cationic drugs caused by downregulation of renal rat organic cation transporter 2 (Slc22a2) and rat multidrug and toxin extrusion 1 (Slc47a1) in ischemia/reperfusion-induced acute kidney injury. Drug Metab Dispos. 2008;36:649-654.
6. Hacker K, Maas R, Kornhuber J, Fromm MF, Zolk O. Substrate-dependent inhibition of the human organic cation transporter OCT2: a comparison of metformin with experimental substrates. PLoS One. 2015;10:e0136451.
7. Padhy AK, Solanki KK, Bomanji J, Chaiwatanarat T, Nimmon TT, Britton KE. Clinical evaluation of 99m Tc diaminocyclohexane, a renal tubular agent with cationic transport: results in healthy human volunteers. Nephron. 1993;65:294-298.
8. 68Ga EDTA imaging and plasma clearance measurement of glomerular filtration rate: comparison to conventional 51 Cr EDTA. J Nucl Med. 2015;56:405-409.
9. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996; 30:359-371.
10. Pentikäinen PJ, Neuvonen PJ, Penttilä A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol. 1979;16:195-202.
11. 11C]metformin as a PET probe to study hepatobiliary transport mediated by the multi-drug and toxin extrusion transporter 1 (MATE1) in vivo. Bioorg Med Chem. 2013;21:7584-7590.
12. Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 2009;86:299-306.
13. Christensen MM, Pedersen RS, Stage TB, et al. A gene-gene interaction between polymorphisms in the OCT2 and MATE1 genes influences the renal clearance of metformin. Pharmacogenet Genomics. 2013;23:526-534.
14. Juillard L, Janier MF, Fouque D, et al. Renal blood flow measurement by positron emission tomography using 15O-labeled water. Kidney Int. 2000;57:2511-2518.
15. Smith HW, Finkelstein N, Aliminosa L, Crawford B, Graber M. The renal clearances of substituted hippuric acid derivatives and other aromatic acids in dog and man. J Clin Invest. 1945;24:388-404.
16. Koepsell H. Polyspecific organic cation transporters and their biomedical relevance in kidney. Curr Opin Nephrol Hypertens. 2013;22:533-538.
17. Masuda S, Terada T, Yonezawa A, et al. Identification and functional characterization of a new human kidney-specific H1/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2 J Am Soc Nephrol. 2006;17: 2127-2135.
18. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010;298: F997-F1005.
19. Nies AT, Hofmann U, Resch C, Schaeffeler E, Rius M, Schwab M. Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS One. 2011;6:e22163.
20. Nozaki Y, Kusuhara H, Kondo T, et al. Characterization of the uptake of organic anion transporter (OAT) 1 and OAT3 substrates by human kidney slices. J Pharmacol Exp Ther. 2007;321:362-369.
21. Groves CE, Suhre WB, Cherrington NJ, Wright SH. Sex differences in the mRNA, protein, and functional expression of organic anion transporter (Oat) 1, Oat3, and organic cation transporter (Oct) 2 in rabbit renal proximal tubules. J Pharmacol Exp Ther. 2006;316:743-752.
22. Bischoff A, Bucher M, Gekle M, Sauvant C. PAH clearance after renal ischemia and reperfusion is a function of impaired expression of basolateral Oat1 and Oat3. Physiol Rep. 2014;2:e00243.
23. Burckhardt G, Bahn A,Wolff NA. Molecular physiology of renal p-aminohippurate secretion. News Physiol Sci. 2001;16:114-118.
24. Komazawa H, Yamaguchi H, Hidaka K, Ogura J, Kobayashi M, Iseki K. Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure. J Pharm Sci. 2013;102:1086-1094.
25. Higgins JW, Bedwell DW, Zamek-Gliszczynski MJ. Ablation of both organic cation transporter (OCT)1 and OCT2 alters metformin pharmacokinetics but has no effect on tissue drug exposure and pharmacodynamics. Drug Metab Dispos. 2012;40:1170-1177.
26. Stage TB, Brøsen K, Christensen MM. A Comprehensive Review of Drug-Drug Interactions with Metformin. Clin Pharmacokinet. 2015;54:811-824.
27. Thévenod F, Ciarimboli G, Leistner M, et al. Substrate-and cell contact-dependent inhibitor affinity of human organic cation transporter 2: studies with two classical organic cation substrates and the novel substrate cd21. Mol Pharm. 2013;10:3045-3056.
28. Ito S, Kusuhara H, Yokochi M, et al. Competitive inhibition of the luminal efflux by multidrug and toxin extrusions, but not basolateral uptake by organic cation transporter 2, is the likely mechanism underlying the pharmacokinetic drug-drug interactions caused by cimetidine in the kidney. J Pharmacol Exp Ther. 2012;340:393-403.
29. Choi MK, Jin QR, Jin HE, et al. Effects of tetraalkylammonium compounds with different affinities for organic cation transporters on the pharmacokinetics of metformin. Biopharm Drug Dispos. 2007;28:501-510.
30. Ciarimboli G, Ludwig T, Lang D, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005;167: 1477-1484.
31. Wensing KU, Ciarimboli G. Saving ears and kidneys from cisplatin. Anticancer Res. 2013;33:4183-4188.
32. Arndt P, Volk C, Gorboulev V, et al. Interaction of cations, anions, and weak base quinine with rat renal cation transporter rOCT2 compared with rOCT1. Am J Physiol Renal Physiol. 2001;281:F454-F468.
33. Minematsu T, Giacomini KM. Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther. 2011;10:531-539.
34. Bachmakov I, Glaeser H, Endress B, Mörl F, König J, Fromm MF. Interaction of beta-blockers with the renal uptake transporter OCT2. Diabetes Obes Metab. 2009;11:1080-1083.
35. Lee N, Duan H, Hebert MF, Liang CJ, Rice KM, Wang J. Taste of a pill: organic cation transporter-3 (OCT3) mediates metformin accumulation and secretion in salivary glands. J Biol Chem. 2014;289:27055-27064.
36. Stabin M, Taylor A, Eshima D, Wooter W. Radiation dosimetry for technecium-99m-MAG3, technecium-99m-DTPA and iodine-131-OIH based on human biodistribution studies. J Nucl Med. 1992;33:33-40.